Transforming the early detection
and intervention of cancer
Our Unique Biomarker
OncAlert Labs develops tests based on patented technology that detects specific protein markers known to indicate an elevated risk for early stage cancers, even prior to observation of visual or physical symptoms.
Actionable Insights for Earlier Oral Cancer
OraMark’s oral rinse collection method is easy to administer and non-invasive for the patient. The test delivers accurate, quantitative results that help optimize patient management and surveillance both pre- and post-biopsy.
Featured News and Events
March 30, 2017 |
Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups; Only 29 Percent Actually Are
Survey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck Cancer reveals low awareness, misconceptions and desire for more information on oral cancer
Mar 27, 2017 |
Oral Cancer Tests Capture Biomarkers Using Saline Rinse
The OncAlert oral cancer product line from Vigilant Biosciences Inc, Fort Lauderdale, Fla, is now available in select markets. The company’s OncAlert oral cancer product line includes the OncAlert oral cancer rapid test and the OncAlert oral cancer lab test, available in countries accepting the CE mark. The tests are based on technology that accurately measures […]
March 22, 2017 |
Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert® Oral Cancer and OncAlert Labs Product Lines
Vigilant Biosciences, Inc. today announced the acceptance of five abstracts regarding data related to studies conducted by the Company to better understand the performance characteristics of a combined salivary CD44 and total protein assay as an aid in the diagnosis of head and neck squamous cell carcinoma (HNSCC).The studies, along with others, helped provide direction for […]